Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access

Fineline Cube Apr 14, 2026
Company Deals

CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China’s NHL Market

Fineline Cube Apr 14, 2026
Company Deals

Erasca Exercises Option to Secure Global Rights to Pan-RAS Molecular Glue ERAS-0015 from Joyo Pharmatech

Fineline Cube Apr 14, 2026
Company Deals

Zuellig Pharma Acquires Cialis Rights for Hong Kong, Macau, and South Korea from Eli Lilly

Fineline Cube Apr 14, 2026
Company Deals

Olymvax Biopharmaceuticals and Westlake University Launch Universal Influenza Vaccine Collaboration

Fineline Cube Apr 14, 2026
Policy / Regulatory

China’s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program

Fineline Cube Apr 14, 2026
Company Drug

Grand Pharmaceutical’s SIR-Spheres Achieves Phase III Success in Unresectable HCC, Supporting China Expansion

Fineline Cube Apr 14, 2026
Company Drug

Zelgen’s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial – Dual JAK/ACVR1 Inhibitor Expands Beyond Myelofusion

Fineline Cube Apr 14, 2026
Company Drug

Wuhan Binhui’s Oncolytic Virus Therapy Awarded Breakthrough Designation by CDE

Fineline Cube Feb 20, 2023

The Center for Drug Evaluation (CDE) website indicates that China-based Wuhan Binhui Biotechnology Co., Ltd’s...

Company Drug

CDE Awards Priority Review to Eisai’s Lecanemab for Early Alzheimer’s Disease

Fineline Cube Feb 20, 2023

The Center for Drug Evaluation (CDE) website indicates that Japan-based Eisai’s (TYO: 4523) lecanemab has...

Company Deals Medical Device

Chunlizhengda to Acquire Majority Stake in Surgimaster for Medical Power Tools

Fineline Cube Feb 20, 2023

Beijing Chunlizhengda Medical Instruments Co., Ltd (HKG: 1858, SHA: 688236) is poised to acquire a...

Company Deals

Duoning Biotech Secures Global Rights to Junzhen’s Cell Counter Products

Fineline Cube Feb 20, 2023

China’s Shanghai Duoning Biotechnology Co., Ltd has entered into a licensing deal with compatriot firm...

Company Deals

Sansure Biotech Partners with Hunan Normal University for Research and Talent Development

Fineline Cube Feb 18, 2023

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has announced a strategic partnership with...

Company Deals

Amcor Acquires Shanghai-Based MDK to Expand Asia-Pacific Footprint

Fineline Cube Feb 18, 2023

Switzerland-based packaging firm Amcor (NYSE: AMCR) has unveiled the signing of a deal to acquire...

Company Drug

CSPC’s NBL-020 Gets NMPA Approval for Clinical Study in Advanced Solid Tumors

Fineline Cube Feb 17, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving the go-ahead from the National...

Company Drug

Kelun Pharma’s Generic Jardiance Gains New Indication in China

Fineline Cube Feb 17, 2023

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has obtained another indication approval in China...

Policy / Regulatory

Hangzhou Singclean Stripped of VBP Status for Artificial Lenses

Fineline Cube Feb 17, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has revealed that Hangzhou Singclean Medical Products Co., Ltd...

Company Deals R&D

Topgen Biopharm Partners with Fudan University for Breast Cancer Gene Detection

Fineline Cube Feb 17, 2023

Zhejiang-based tumor precision medicine specialist Topgen Biopharm Co., Ltd has entered into a strategic partnership...

Company Deals Digital

By-Health Partners with Meituan’s Drug Purchase APP for New Retail Expansion

Fineline Cube Feb 17, 2023

China-based By-Health Co., Ltd. (SHE: 300146) has entered into a strategic partnership with Meituan’s drug...

Company Deals

Kangtai Biological Partners with Pakistani Firm for Pneumonia Vaccine Expansion

Fineline Cube Feb 17, 2023

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced a strategic partnership with...

Company Deals Medical Device

Shanghai-Based REMD Raises Series A+ Funding for Electroporation Device Expansion

Fineline Cube Feb 17, 2023

Shanghai-based REMD, a leading manufacturer of irreversible electroporation devices, has reportedly raised over RMB 100...

Company Drug

NMPA Approves Keverprazan for Duodenal Ulcers and Reflux Esophagitis

Fineline Cube Feb 17, 2023

The National Medical Products Administration (NMPA) has granted approval to Jiangsu Carephar Pharmaceutical Co., Ltd’s...

Company

Organon Reports Q4 and Full-Year 2022 Financials with Revenue Declines

Fineline Cube Feb 17, 2023

US-based Organon Inc. (NYSE: OGN) has released its Q4 and full-year 2022 financial results. Global...

Company Deals Digital R&D

WinHealth Pharma Taps Baidu’s ERNIE Bot for Rare Disease Services

Fineline Cube Feb 16, 2023

China-based Hong Kong WinHealth Pharma Group Ltd’s Bo’Ao Winhealth Rare Disease Medical Center has accessed...

Company

Eppendorf to Start Construction on New Shanghai Production Site

Fineline Cube Feb 16, 2023

Germany-based life sciences service provider Eppendorf is set to begin work on a new production...

Company Deals

InnoCare Regains Rights to Orelabrutinib as Biogen Terminates Licensing Agreement

Fineline Cube Feb 16, 2023

Beijing InnoCare Pharma Tech Co., (HKG: 9969), a China-based biotech focusing on cancer and autoimmune...

Company Drug

AIM Vaccine Gains Approvals for COVID-19 mRNA Vaccine Trials in Pakistan

Fineline Cube Feb 16, 2023

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving separate approvals in Pakistan to...

Company Drug

Innovent Biologics Initiates Phase III CLEAR Study for Picankibart in Psoriasis

Fineline Cube Feb 16, 2023

China-based Innovent Biologics (HKG: 1801) has announced the first subject dosing in the Phase III...

Posts pagination

1 … 546 547 548 … 650

Recent updates

  • Grand Pharmaceutical’s SIR-Spheres Achieves Phase III Success in Unresectable HCC, Supporting China Expansion
  • China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access
  • Zelgen’s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial – Dual JAK/ACVR1 Inhibitor Expands Beyond Myelofusion
  • China’s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program
  • CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China’s NHL Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Grand Pharmaceutical’s SIR-Spheres Achieves Phase III Success in Unresectable HCC, Supporting China Expansion

Company Deals

China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access

Company Drug

Zelgen’s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial – Dual JAK/ACVR1 Inhibitor Expands Beyond Myelofusion

Policy / Regulatory

China’s NHSA Selects 31 Innovative Drugs for Historic Reference Drug Pre-Communication Program

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.